dr. weber on rationale for the checkmate-238 trial in melanoma
Published 4 years ago • 116 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:17
dr. weber on checkmate-238 compared to other trials in melanoma
-
1:44
dr. weber on the updated analysis of the checkmate-238 trial in melanoma
-
1:42
dr. weber on biomarker data from checkmate-238 for melanoma
-
1:50
dr. weber discusses updated data for checkmate-238
-
5:30
jeffrey s weber, asco 2018 – resected stage iii melanoma and the checkmate 238 trial
-
2:18
dr. jeffrey weber on checkmate-064 trial for advanced melanoma
-
5:44
4-year results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma
-
1:05
dr. weber on the future of checkpoint inhibitors in melanoma
-
7:04
checkmate 238: adjuvant checkpoint therapy after melanoma resection
-
1:22
dr. weber on nivolumab versus chemotherapy in advanced melanoma
-
0:58
impact of checkmate-238 results for patients with melanoma
-
2:56
encouraging phase 3 checkmate 238 data: adjuvant nivolumab in resected stage iii/iv melanoma
-
1:50
dr. weber on research efforts examining neoadjuvant approaches in melanoma
-
0:59
dr. weber on the fda approval for fixed-dose of nivolumab
-
2:05
dr. jeffrey weber explores nivolumab in advanced melanoma
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
1:59
checkmate 238: nivolumab versus ipilimumab in stage iii melanoma
-
1:28
dr. jeffery s. weber on sequencing of nivolumab, ipilimumab in metastatic melanoma
-
3:02
checkmate 238 results presented at esmo 2017